Communiqués Vanda Pharmaceuticals Inc.

Actions

VNDA

US9216591084

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 19:32:03 09/09/2026			Varia. 5j.	Varia. 1 janv.
5,245 ^USD	-1,59%		-4,97%	-40,42%

24/08	Le traitement de Vanda Pharmaceuticals contre une maladie de peau obtient la désignation de médicament orphelin dans l'UE	MT
10/08	Vanda Pharmaceuticals Inc. : B. Riley optimiste sur le dossier	ZM

Communiqués

02/09	Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences	PR
24/08	Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission	PR
22/08	NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.	PR
05/08	Vanda: Q2 Earnings Snapshot	AQ
05/08	Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results	PR
29/07	Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026	PR
16/07	Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe	PR
15/07	NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment	PR
10/07	Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit	PR
07/07	Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S	PR
27/05	Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis	PR
08/05	Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences	PR
06/05	Vanda: Q1 Earnings Snapshot	AQ
06/05	Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results	PR
04/05	Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years	PR
01/05	Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years	PR
29/04	Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026	PR
29/04	Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence	PR
22/04	Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors	PR
09/04	Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines	PR
08/04	Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	PR
19/03	Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods	PR
03/03	Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years	PR
26/02	Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference	PR
25/02	Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis	PR